References
- Quintas-Cardama A, Cortes J E. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006; 81: 973–988
- Kantarjian H M, Cortes J E, O'Brien S, Luthra R, Giles F, Verstovsek S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 2004; 104: 1979–1988
- Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873–2878
- Hughes T P, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley M L, et al. for the International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432
- Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204–2205
- Mauro M J, Druker B J, Maziarz R T. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004; 28(Suppl 1)S71–S73
- Merante S, Orlandi E, Bernasconi P, Calatroni S, Boni M, Lazzarino M. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005; 90: 979–981
- Breccia M, Diverio D, Paneb F, Nanni M, Russo E, Biondo F, et al. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph+ CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon. Leuk Res 2006; 30: 1577–1579
- Rousselot P, Huguet F, Rea D, Legros L, Cayuela J M, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58–60
- Michor F, Hughes T P, Iwasa Y, Branford S, Shah N P, Sawyers C L, et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267–1270
- Kantarjian H M, O'Brien S, Cortes J E, Shan J, Giles F J, Rios M B, et al. Complete cytogenetic and molecular responses to interferon-a based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97: 1033–1041
- Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001; 98: 3074–3081
- Mahon F X, Delbrel X, Cony-Makhoul P, Fabères C, Boiron J M, Barthe C, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 2002; 20: 214–220